Introduction
Our group recently identified Ras homolog member I (ARHI), a novel maternally imprinted tumor suppressor gene that encodes a 26 kDa GTP-binding protein with 60% homology to Ras and Rap (Yu et al., 1999) . ARHI is expressed in normal ovarian and breast epithelial cells, but its expression is lost or markedly downregulated in the majority of ovarian and breast cancers. The ARHI gene maps to a locus on human chromosome 1p31 that has been associated with a high frequency of LOH (40%) in ovarian and breast cancers (Yu et al., 1999; Peng et al., 2000) . The gene is monoallelically expressed and maternally imprinted in normal cells and is the first imprinted tumor suppressor gene identified in adult tumors. Introduction of this gene into cancer cells that lack ARHI expression truncates signaling through Ras/ MAP, activates JNK, induces p21
, downregulates cyclin D1, and triggers apoptosis (Yu et al., 1999; Yu Y, Bast RC, unpublished data) . Loss of any of these functions may contribute to oncogenesis. Expression of human ARHI in mice is associated with small size, infertility and inhibition of lactation . These data suggest that ARHI may function as a negative regulator of growth and development of breast and gonadal tissues.
A large superfamily (>100 members) of monomeric GTP-binding proteins structurally related to the Ras oncogene proteins has been described over the last 15 years (Bounre et al., 1991; Boguski and McCormick, 1993) . The Ras family of proto-oncogenes is commonly activated in human cancers by mutagenesis or by functional activation. Functional activation of the Ras pathway has been reported in both ovarian and breast cancers (Clark and Der, 1995; Patton et al., 1998) . The mammalian Ras superfamily members serve as molecular switches to regulate a diverse array of cellular functions, including cellular proliferation, differentiation, intracellular vesicular trafficking, cell growth, signal transduction, and cytoskeletal control (Downward, 1992; Ridley and Hall, 1992; Tisdale et al., 1992; Rodriguez-Viciana et al., 1994) . Despite sequence differences between subfamily members, all Ras-related proteins are GTPases with five highly conserved domains (G1-G5) mediating GTP binding and hydrolysis (Lowy and Willumsen, 1993) . Ras-related GTPases cycle between a GTP-bound (presumably active) form and a GDP-bound (presumably inactive) form and are regulated by proteins that affect GDP dissociation, GTP association, or the rate of GTP hydrolysis (Bounre et al., 1991) .
Many members of the Ras superfamily are protooncogenes or positive growth regulators. ARHI on the other hand functions as a tumor suppressor gene (Yu et al., 1999) . Two recently identified Ras-related genes (Rig, Rerg) were also shown to function as negative growth regulators (Finlin et al., 2001; Ellis et al., 2002) . Rig is a farnesylated inhibitor of cell growth and transformation. Rerg bears 40% homology to ARHI and is an estrogen-regulated growth-inhibitory gene whose function is lost in breast cancer. Unlike other Ras superfamily members, ARHI has several unique features. ARHI contains a number of conserved sequences in the GTP-binding domains, but differs from Ras in residues critical for GTPase activity and in the effector domain. Most interestingly, ARHI contains a unique extension of 34 amino acids at the N-terminus, which is rarely encountered in other Ras family members.
In the present study, we conducted experiments at the biochemical and cellular levels to establish the ARHI's structure and function relations. We expressed recombinant ARHI protein to characterize its GTP binding and GTPase activities, and employed site-directed mutagenesis to explore its structure-function relations. Our observations confirmed that ARHI is indeed a GTPbinding protein but has only modest GTPase activity. Unlike the Ras oncogene, ARHI inhibits cell growth and loss of its expression may contribute to development of the breast and ovarian cancers.
Results

ARHI is a GTP-binding protein
Sequence comparison revealed that all five GTPbinding-related domains observed in the Ras family are conserved in ARHI (Figure 1 ). To determine if these conserved domains in ARHI can indeed bind GTP, recombinant ARHI protein was partially purified from Escherichia coli transformed with a plasmid containing ARHI cDNA (Figure 2a, b) . In addition, transient expression of wild-type and mutant ARHI in transfected HEK293 cells was in similar levels ( Figure 2c ). As was predicted from its primary sequence, ARHI bound [ 35 S]GTPgS in a rapid, saturable, and time-dependent fashion. GTP binding to ARHI was rapid, with halfmaximal binding at 4 min and maximal binding by 15 min at 251C (Figure 2d ). At saturation, the calculated GTP : ARHI molar ratio was 0.38 : 1. Considering sample loss from filtration during the assay (Bollag and McCormick, 1995) , as well as some improper protein folding of the recombinant protein, the actual stoichiometry for nucleotide/protein ratio may be close to 1 : 1.
Binding of GTP to ARHI was Mg
2+
-dependent (Figure 2e) . In contrast to Ras that shows increased exchange rates at low Mg 2+ concentration (Hall and Self, 1986) , GTP binding and GDP binding to ARHI were minimal when the calculated Mg 2+ concentration was at 0.5 mm, but increased at higher Mg 2+ concentrations, reaching a maximal value between 1 and 10 mm of MgCl 2 (Figure 2e ). To test the specificity of its nucleotide binding, ARHI was incubated with different nucleotides in addition to [
35 S]GTPgS. Binding of [ 35 S]GTPgS was blocked by 250 mm of GTP, GTPgS, and GDP, whereas ATP, UTP, and CTP did not compete for any binding even at 250 mm concentrations (Figure 2f ). At lower concentration (5 mm) of guanine nucleotides, however, GDP binds poorly to ARHI, indicating that ARHI has a lower affinity for GDP than GTP (Figure 2d) . In experiments to examine the effects of site-directed mutations on the GTP binding of ARHI, we found that wild-type and most mutant ARHIs, including the CAAX mutant ARHI CX , the N-terminal deletion mutant ARHI ND , and the mutant ARHIA 46V exhibited similar GTP-binding affinities, whereas the mutant ARHI S5IN had significantly reduced GTP-binding activity (Figure 2g ), suggesting this residue may be directly involved in GTP binding.
ARHI exhibited modest intrinsic GTPase activity
To assess GTPase activity, ARHI was loaded with [ 3 H]GTP, free nucleotides were washed away, and bound [ 3 H]GTP was subjected to hydrolysis in the presence of 10 mm MgCl 2 . At indicated time points, the reaction was stopped, and the amount of nucleotides still bound to ARHI was measured by the rapid filtration method or was eluted and analysed by TLC. Under these conditions, ARHI produced very slow GTP hydrolysis to GDP compared to H-Ras, suggesting a very low intrinsic GTPase activity (Figures 3a, d and 4a) . Mutation of Ala 46 to Val further reduced GTPase activity (Figure 3b , e), suggesting that mutation in this residue destroyed most, if not all, of the GTPase activity. GTPase activity was lower but still present in the ARHI S51N mutant (Figure 3b ). When the three conserved residues critical for Ras GTPase activity were substituted in ARHI (A 46 exhibited enhanced GTPase activity (Figure 4a, b) .
ARHI is associated with GTP in vivo
Considering the modest GTPase activity in ARHI, we examined which guanine nucleotides are bound by ARHI in vivo. Cos-7 cells were transfected either with ARHI or H-Ras expression constructs and labeled with 32 Phosphorus. Proteins labeled with [ 32 P] guanine nucleotides were recovered by immunoprecipitation. The radioactive nucleotides were analysed by TLC as in Figure 4c . H-Ras formed complexes almost exclusively with GDP (92%). In contrast, 78% of ARHI proteins exist as the putatively activated GTP-bound form in resting cells, suggesting that ARHI may normally be maintained in a constitutively active state in vivo, possibly resulting from insufficient GTP hydrolyzing.
ARHI does not bind to the Ras effector Raf but downregulate MAPK activity
To test whether ARHI interacts with Raf, a specific effector for Ras subfamily members, we examined the ability of ARHI to bind the Ras-binding domain (RBD) of Raf in an in vitro pull-down assay. Interaction between Raf-1-RBD and Ras was indicated as positive control. As seen in Figure 5a, In addition, using sense and antisense ARHI constructs, we further demonstrated that ARHI even downregulated MAPK activity. The results from EGF stimulated MAPK activity in NIH 3T3 cells showed that expression of ARHI reduced the basal MAPK activity and shortened the duration of MAPK activation in response to EGF without affecting that induced by TPA, suggesting that ARHI could specifically downregulate EGF stimulated MAPK activity ( Figure 5c ).
ARHI is post-translationally prenylated and the CAAX box is critical for ARHI's membrane association ARHI bears a CIIM (CAAX box) sequence at its Cterminus, suggesting that this sequence might serve as an anchor to the cell membrane. Point mutation at Cys 226 to Ser (CX mutant) disrupted ARHI's association with the cell membrane ( Figure 6 ). In HEK293 cells transfected with GFP-ARHI (wild-type and CX mutant) fusion constructs, a portion of wild-type GFP-ARHI fusion protein was found to associate with the cell membrane (Figure 6a ), whereas the GFP-ARHI CX mutant protein did not (Figure 6b ). Consistently, immunofluorescence staining of Cos7 cells transfected with ARHI plasmid also demonstrated a membrane association of the ARHI protein (data not shown). In addition to membrane localization, a substantial quantity of ARHI is distributed in the cytoplasmic space, resulting, in part, from an overexpression of ARHI. To investigate the normal distribution of ARHI in untransfected cells, we examined normal ovarian epithelial cells in which a low level of ARHI was consistently expressed. Immunoblotting of the isolated membrane and cytosolic fractions showed that ARHI was only detected in the membrane fraction, supporting that in normal cells ARHI is localized mainly in the cell membrane ( Figure 6c ). In a more detailed subcellular fractionation experiments, we observed that ARHI was detected mainly in the plasma membrane fraction with a small portion of ARHI also detected in other subcellular organelles. Again, no ARHI was detected in the cytosol fraction (data not shown). To further confirm that ARHI's membrane association is through prenylation at the Cys 226 residue of the CAAX box, we performed an in vivo labeling experiment with [ 3 H]mevalonolactone. Similar to the H-Ras protein, wild-type ARHI was also covalently For the quick filtration assay, the reaction mixture was stopped by quick filtration through a nitrocellulose filter, followed by washing with cold buffer. Radioactivity that remained bound to ARHI was determined by scintillation counting and expressed as a percentage of counts at the initiation of the experiment. For the TLC method, beads were washed, bound nucleotides were eluted and nucleotides resolved by polyethyleneimine cellulose TLC as described under Materials and methods. For (b), autoradiograms were quantified by scanning densitometry and the data expressed as a percentage of GDP in the total bound guanine nucleotides at 40 min of the assay for three separate experiments modified (Figure 6d ). In contrast, the CX mutant that contains C226S mutation did not show any modification. Taken together, these results confirmed that Cys 226 residue was post-translationally modified by prenylation at the Cys 226 residue. Consistent with a requirement for membrane binding for its biological activity, the CX mutant also exhibited reduced growth inhibitory activities than the wild-type ARHI in HEK293 cells and Hey ovarian cancer cells (Figure 7 ).
Mutagenesis and biological analysis of ARHI
Aligning the sequences of ARHI with Ras ( Figure 1 ) revealed a number of potentially interesting amino-acid substitutions, which could affect ARHI's functional properties. First, the highly conserved G , the C-terminal membrane association site, as well as the N-terminal extension unique to ARHI. ARHI bears a CIIM (CAAX box) sequence at its C-terminus, suggesting that this sequence might anchor ARHI to the cell membrane. A point mutation of Cys to Ser at residue 226 (CX mutant) led to the loss of ARHI's association with the cell membrane (Figure 6a, d) . In HEK293 cells transfected with GFP-ARHI (wild-type and CX mutant) fusing constructs, a portion of wild-type GFP-ARHI fusing proteins were found to associate with the cell membrane, whereas no membrane association was observed with the GFP-ARHI CX mutant proteins (Figure 6a, b) . Consistent with membrane-binding requirement for its biological activity, the CX mutant protein exhibited a reduced growth inhibitory activity than did wild-type ARHI in HEK293 cells and Hey ovarian cancer cells (Figure 7) .
Amino-acid sequence analysis showed that ARHI substituted several critical residues that were highly conserved in Ras related to its GTPase activity. To test whether the substituted A 46 , K
93
, and G 95 in ARHI Figure 4 ARHI is an impaired GTPase. Similar GTPase activity assays in Figure 3 were performed in H-Ras, wild-type, and mutant ARHI proteins to compare their GTPase activities. Wild-type ARHI showed much lower intrinsic GTPase activity compared to H-Ras (a and b). Mutant ARHI A46G and double mutant ARHI A46G/G95Q partially restored GTPase activity, whereas other individual or multiple mutants exhibited little or no impact on the GTPase activity compared to wild-type ARHI. In an in vivo
32
Pi labeling assay, wild-type ARHI or H-Ras construct or the empty was transfected to Cos-7 cells and incubated with 32 Pi. Labeled ARHI and H-Ras were immunoprecipitated with anti-ARHI or anti-H-Ras antibody and protein A/G-Sepharose. Guanine nucleotides bound to these proteins were separated by TLC and quantitated by scanning densitometry. Predominant GTP-bound (ARHI) or GDP-bound forms (H-Ras) were found by autoradiogam contribute to ARHI's modest GTPase activity, we mutated these residues to the conserved residues G 12 , A
59
, and Q 61 in Ras, respectively. The A46G and G95Q mutations seemed to play a greater role in restoring ARHI's GTPase activity than did the K93A mutant. Mutant ARHI A46G and double mutant ARHI A46G/G95Q
partially restored GTPase activity, while other individual or multi-mutants exhibited little or no impact on the GTPase activity (Figure 4a, b) . When we transfected ARHI mutant constructs containing the Ras-related residues, the repaired GTPase activity was increased and growth inhibitory activity was decreased (Figure 8 ), suggesting that the growth inhibitory function of ARHI correlated with its GTP-bound state. Other mutants corresponding to dominant-positive mutant Val 12 or dominant-negative mutant Gln 17 in Ras, respectively, were tested for their ability to bind and hydrolyze GTP. As with Ras, mutation of Ser 51 to Asn 51 in ARHI (S51N mutant) reduced GTP binding (Figure 2e) , indicating an important role of this residue in GTP binding or overall structure of the protein. Mutation of A 46 to V 46 (A46 V mutant, equivalent to the transforming mutation G12 V in Ras) further reduced intrinsic GTP hydrolysis and increased the ability of ARHI to inhibit cell growth (Figures 3e and 7) . These results demonstrated that the substitution of A 46 , K
93
, and G 95 in ARHI, the highly , and Q 61 in the Ras family, caused at least a partial decrease in GTPase activity of ARHI and contributed to the constitutively GTP binding by ARHI.
The most striking effect on ARHI function was with the N-terminal truncated mutant (ND mutant). Deletion of ARHI's unique N-terminal extension nearly abolished its inhibitory effect on cell growth (Figure 7) . The observed loss of inhibitory function in the ND mutant was not resulted from the levels of protein expression (Figure 2b ). This alteration in functions was Figure 7 Growth inhibition of wild-type and mutant ARHIs in normal and tumor cells. Point mutations and deletions were made in ARHI with the Quickchange mutation kit (Stratagene) using pCDNA3-ARHI as a template. Wild-type and mutant ARHI constructs were transfected into HEK293 and Hey ovarian cancer cells and colony formation were measured using a G418 selected colony assay. No significant inhibitory effect was observed with GST compared to vector alone. Wild-type ARHI strongly inhibited cell growth with sharply reduced numbers of colonies. Mutation of CAAX (mutant CX) and inhibition of GTP binding (mutant S51N) decreased ARHI's inhibitory effect (Po0.05, compared to wild-type ARHI), destroying ARHI's GTPase activity (mutant A46 V) further increased ARHI's growth inhibition effect (Po0.05). The most striking effect on growth inhibition was seen with the mutant ND. Deletion of the N-terminus of ARHI nearly abolished ARHI's growth inhibitory effect (Po0.01) Figure 8 Growth inhibition of ARHI mutated in the GTPase catalytic regions in normal and tumor cells. Similar experiments to those shown in Figure 7 were carried out with the exception that ARHI mutations were focused on putative GTPase catalytic regions. Results from Figure 5 showed that mutant ARHI A46G and double mutant ARHI A46G/G95Q partially restored GTPase activity, whereas other individual or multiple mutants exhibited little or no impact on GTPase activity. Consistently, G-418 selected colony formation showed that ARHI mutants with increased GTPase activity produced less growth inhibition. The ND mutant had the least inhibitory effect on cell growth the most significant among mutants we generated, including all mutants that affected the GTPase activity of ARHI. These observations suggest that the Nterminus of ARHI plays an important role in ARHI's growth inhibitory function.
Discussion
Ras proteins are small GTPases that operate as binary molecular switches in key signal transduction pathways to regulate cell growth, motility, and invasion. Many Ras family members function as proto-oncogenes. When activated or overexpressed, Ras and Rac can transform 3T3 cells. ARHI shares significant sequence homology with the Ras family members (54-59% with Ras subfamily and 56-62% with Rap subfamily) (Yu et al., 1999) . Like most other Ras family members, the primary amino-acid sequence of ARHI contains highly conserved GTP-binding motifs (G1-G5) and the membrane localization CAAX box motif at its C-terminus (Figure 1 ). However, unlike Ras, ARHI inhibits cell growth, motility, and invasion, despite its homology to Ras. Recently, Rerg (Finlin et al., 2001) and Rig (Ellis et al., 2002) , two additional Ras family members, have also been shown to possess growth inhibitory properties. We hypothesize that differences in protein structure underlie these dramatic differences in function. Moreover, growth stimulatory and growth inhibitory GTPbinding proteins are likely to associate with different partners and are likely to regulate functionally distinct signaling cascades.
In this study, we expressed ARHI, characterized its nucleotide binding and GTPase activities, and correlated its structure-function relations. We found that ARHI is a GTP-binding protein and has intrinsic GTPase activity even though the activity is quite low. As a characteristic of most Ras-like proteins, such as human Ras (McGrath et al., 1984; Reuther and Der, 2000) and other small G-proteins (Bhullar and Haslam, 1987) binding of GTP to ARHI is rapid and saturable. As seen in Figure 2, , and G 60 residues in the G3 domain known to be important for interaction with Mg 2+ /GTP (Willumsen et al., 1986) residues, respectively. These residues are also important for maintaining GTPase activity in Ras proteins.
Subcellular protein localization is known to be important for their function. In this regard, targeting signaling molecules to their appropriate subcellular compartments is usually the first and crucial step in the activation of signal pathways. Stable membrane association of Ras or Rho family members can affect the cytoskeletal organization, protein endomembrane trafficking, regulation of mitosis, activation of transcription, and transformation in a cell compartment-specific manner (Choy et al., 1999; Murphy et al., 1999; Muller et al., 2002) . Inhibition of membrane association has led to the loss of function and translocation to a different subcellular compartment (Ashar et al., 2000) . ARHI contains a typical CAAX motif and a basic cluster motif (potentially functioning as a nuclear localization signal) near the C-terminus, consistent with stable membrane targeting to the plasma membrane, cytoskeleton, or nuclear membrane (Hofemeister et al., 2000) . Implications for the potential localization and function of ARHI remain to be clarified. Mutation of the CAAX box led to a loss of ARHI's membrane association and a decrease in biological activity, confirming that ARHI's biological function is at least partially dependent on post-translational prenylation at C 226 and association with the plasma membrane.
ARHI differs from Ras in the effector region, suggesting that it is likely to interact with different effector molecules. The effector motif sequence YDP-TIEDSYRK is conserved in all Ras and Rap proteins. Crystal structures of Ras/Rap-Raf complexes have indicated that charged residues, D, E, D, R, K in this region, interact directly with the Ras effector, Raf (Nassar et al., 1995; Chen et al., 1996) . ARHI has a corresponding sequence of YLPTIENTYCQ (Figure 1) , in which most of the charged residues have been replaced by the noncharged residues L, N, C, and Q, suggesting that ARHI may interact with an effector other than Raf. In addition, in contrast to most Ras members, two cysteine residues are present, which may form an extra disulfide bond to further alter the conformation of ARHI in this region. In this study we found that, as expected, ARHI failed to interact with the RBD of Raf kinase (Figure 5a ). This is consistent with the notion that ARHI interacts with other effector molecules and participates in a distinct downstream signaling pathway. Interestingly, even though ARHI did not bind directly to Raf, ARHI nevertheless inhibited EGF-stimulated MAPK activity (Figure 5c ), suggesting that ARHI might downregulate Ras/MAPK signaling pathway through an unknown mechanism.
Aside from the sequence differences in their effector domain, the highly conserved G , and G 95 in ARHI. This difference is preserved in bovine and swine ARHI analogues (YY, RZL, and RCB, unpublished data). Mutation of these residues in Ras to a wide range of amino acids reduced the intrinsic Ras GTPase activity, activates the protein, and confers oncogenicity on Ras (Seeburg et al., exhibited increased GTPase activity, whereas other individual or multiple mutants had no or a minor effect on the GTPase activity ( Figure  4a, b) . ARHI mutants with increased GTPase activity produced less growth inhibition (Figure 8) , suggesting that the inhibitory function of ARHI was, at least partially, related to its GTP-bound state. Although ARHI has a very low GTPase activity, mutation of A 46 to V 46 in ARHI (equivalent to position V 12 in Ras) resulted in a further decrease in ARHI's intrinsic GTPase activity (Figure 3e) , and led to an increased ability of ARHI to inhibit cell growth. A marked decrease in GTP/GDP cycling in ARHI suggests that this molecule has lost a basic regulatory mechanism by which most Ras family members regulate protein activity and function. These results also suggest that alternative regulation mechanisms may exist to regulate ARHI's activity, such as the level of protein expression or protein-protein interaction. Indeed, in addition to the potential effector domain, possession of a large N-terminal extension may provide ARHI extra protein domain(s) to interact with other signaling proteins.
Structural divergence of ARHI suggests that the unusual large N-terminal extension may play a critical role in ARHI's function. Most members in Ras superfamily, with the exception of the Rad/Rem/Gem subfamily and Rnd3, do not contain such a large Nterminal extension (Maguire et al., 1994; Zhu et al., 1995; Nobes et al., 1998; Piddini et al., 2001) . Sequence analysis of this extension in ARHI suggests that a single a-helix may exist in this region. Deletion of this Nterminal extension essentially abrogated the inhibitory effect of ARHI on cell growth (Figure 7 ) without affecting its GTP-binding and protein expression levels (Figure 2c, e) , suggesting that the N-terminus of ARHI plays a unique and important role in ARHI's inhibitory activity. We have shown that the ND mutant was still able to bind GTP (Figure 2e ) and could be recognized by anti-ARHI antibody in immunoprocipitation experiments (data not shown), suggesting that the reduced inhibitory function of the ND mutant does not result from reduced protein expression levels or abnormality in conformation. On the other hand, other mutations of ARHI related to ARHI's GTP binding or hydrolyzing exhibited less alteration in ARHI's cell inhibitory function. This observation further supports our assertion that, because of modest GTPase activity, the regulation of ARHI's function does not depend primarily on the regulation of GTP/GDP cycle. Identification of proteins that interact with ARHI via this region may be very informative in elucidating the underlying mechanisms by which ARHI downregulates tumor growth in ovarian and breast cancers.
Materials and methods
Reagents and enzymes
All chemicals and nucleotides were purchased from SigmaAldrich. [ H]mevalonolactone (1 mCi/ml) was purchased from American Radiolabeled Chemical Inc. Restriction enzymes and DNA modification enzymes were from Roche Molecular Biochemicals. Plasmid DNA purification kits were from Qiagen.
Construction of wild-type or mutant ARHIs and expression in E. coli Full-length ARHI, starting at the first in-frame ATG and extending to the stop codon (from nt 3355 to 4144, Luo et al., 2001) , or mutant ARHIs with truncation of either the first 34 residues of the N-terminus (assigned as ND mutant, from nt 3458 to 4144, Luo et al., 2001) or the last 25 residues (assigned as CD mutant, from nt 3355 to 4066, Luo et al., 2001) were generated by the polymerase chain reaction (PCR) using a plasmid containing ARHI cDNA, including untranslated regions as template. The resulting 0.7-kb (full-length) or 0.6-kb (ND or CD mutants) DNA was subcloned into NcoIEcoRI-digested pET-32 expression vector (Novagen). cDNAs encoding other mutant ARHIs were excised from the corresponding mutant plasmids (see next section for details) and subsequently subcloned into pET-32 or pET-42 vectors to express the mutant ARHIs in E. coli. An N-or C-terminus 6-His-tag was added to the recombinant proteins to facilitate purification. The full-length and CAAX box-truncated ARHI cDNAs (nt 3355-4144 and nt 3155-4132, Luo et al., 2001) were also subcloned into the pEGFP-N1 mammalian expression vector (Clontech) to express ARHI with GFP fused to the N-terminal site in mammalian cells.
Recombinant plasmids were transformed into BL21 (DE3) cells (Novagen) and grown at 371C to mid-exponential phase in LB medium with 100 mg/ml ampicillin. The expression of 6-His-tagged ARHI was induced in the presence of isopropyl-dthiogalactopyranoside (IPTG) at 161C for 20 h. The fusion proteins were affinity-purified from the soluble fraction of cell extracts with Talont Sepharose beads (Novagen) as described in the manufacturer's protocol. During the purification, the following buffers were employed. Lysis buffer: 20 mm Tris at pH 7.5, containing 500 mm NaCl, 10% glycerol, 5 mm MgCl 2 , 5 mm b-mercaptoethanol, 500 mm GTP, 0.4% NP-40, 1 mm PMSF, 5 mm imidazole and 1 Â Completet protease inhibitor (Roche). Washing buffer was the same as lysis buffer except that the concentration of NP-40 was reduced to 0.1%. The elution buffer was the same as the washing buffer, with the imidazole concentration increased to 250 mm. The purity of the recombinant proteins was checked by SDS-PAGE analysis and the purified protein was saved at -201C in a pH 7.6 Tris buffer with 50% glycerol.
Site-directed mutagenesis
A QuickChanget site-directed mutagenesis kit (Stratagene) was used to generate different mutants of ARHI. Briefly, synthetic oligonucleotide primers containing the mutated sequences were made and mixed with components of the thermal cycling reaction that contained a supercoiled doublestranded plasmid pcDNA3-Y2 with a full-length ARHI cDNA in vector pcDNA3 (Invitrogen) and a G418 eucaryotic expression vector as template. The following mutant plasmids were generated: pCY2 ), pCY2 C226S (to delete the CAAX box), and pCY2 ND (to delete the N-terminal extension). cDNA encoding glutathione S-transferase (GST) was also subcloned into the same vector as a control plasmid (pC-GST) for transfection experiments. All constructs were confirmed by DNA sequencing.
Cell culture, transfection, and clonogenic assays HEK293 human embryo kidney cells, Hey human ovarian cancer cells, and MDA-MB-468 or SKBr3 human breast epithelial cancer cells were grown at 371C to near confluence in Dulbecco's modified Eagle's medium containing 10% fetal calf serum. Wild-type and mutant ARHI plasmids were transfected into different cell lines by using Lipofectenet (Bio-Rad), as described by the supplier. At 4 h after transfection, the medium was replaced with Dulbecco's modified Eagle's medium with 10% fetal bovine serum. After incubation for 48 h at 371C, transfected cells were trypsinized and seeded into 100-mm dishes. Selection medium with G418 (1000 mg/ml) was added. After 2 weeks, colonies were stained with 0.1% Coomassie blue in 30% methanol and 10% acetic acid and then counted using a Chemilmager 550t system (Alpha Innotech). Cells that expressed GFP-tagged wild-type ARHI or the CAAX-truncated mutant ARHI were observed under fluorescence microscopy 24 h after transfection.
Guanine nucleotide binding
GTP binding to ARHI protein was determined using a nitrocellulose filtration assay (Zheng et al., 1995) . Briefly, ARHI or mutant ARHI (1 mm) was first incubated with GDP in loading buffer (20 mm Tris-HCl, pH 7.6, 100 mm NaCl, 2 mm EDTA, 1 mm DTT, 10 mm GDP, and 100 mm AMP-PNP) for 5 min at 251C. The GDP-loaded G-protein then was incubated in 100 ml of the reaction buffer (20 mm Tris-HCl, pH 7.6, 100 mm NaCl, 1 mm DTT, 100 mm AMP-PNP, and 1 mg/ ml BSA) containing the indicated concentrations of MgCl 2 and 5 mm [ 35 S]GTPgS or [ 3 H]GTP at 251C with end-to-end rotation. When needed, EDTA was added, and the concentration of free Mg 2+ was calculated (Sunyer et al., 1984) . At each time point, aliquots of 15 ml were withdrawn and added to 5 ml ice-cold termination buffer (20 mm Tris-HCl, pH 7.6, 100 mm NaCl, and 1 mm DTT) containing the same concentrations of MgCl 2 that were used in the binding assay. The terminated reactions were filtered immediately through BA85 nitrocellulose filters (Schleicher & Schuell), followed by washing with 15 ml of icecold termination buffer. The radioactivity remaining on the filters was measured using a scintillation counter.
To determine the specificity of nucleotide binding, recombinant ARHI protein was incubated in the reaction mixture with or without competing nucleotides. The reaction mixture contained 20 mm Tris-HCl, pH 7.6, 100 mm NaCl, 1 mm EDTA, 10 mm MgCl 2 , 1 mm DTT, 100 mm AMP-PNP, 1 mg/ ml BSA, 1 mm ARHI protein, 1 mm [ 35 S]GTPgS, and 250 mm of competing unlabeled nucleotides (ATP, CTP, UTP, GTP, GDP, and GTPgS). After incubation at 251C for 30 min, the samples were immediately filtered on BA85 nitrocellulose filters and counted as described above. The amount of [ 35 S]GTPgS bound in the absence of competitors was considered to be 100% binding.
GTPase assay
Recombinant ARHI proteins (1 mM) were preloaded with 10 mM [ 3 H]GTP in 80 ml of loading buffer (20 mm Tris-HCl, pH 7.6, 25 mm NaCl, 4 mm EDTA, 1 mm DTT, and 1 mg/ml BSA) for 10 min at 301C. The mixture was placed on ice and MgCl 2 was added to a final concentration of 17 mm. Nucleotide exchange was started by adding 15 mm MgCl 2 and 1 mm unlabeled GTP (Zheng et al., 1995) . After filtration through prewetted nitrocellulose filters (BA85) and washing with cold termination buffer as described above, the amount of radioactivity that remained bound to the protein was determined by scintillation counting.
Alternatively, GTPase activity was measured by thin layer chromatography (TLC) (Park et al., 1993) . To identify the hydrolyzed products of GTP, recombinant ARHI proteins (15 mg) on 30 ml of Talont beads were loaded with [a 32 P]GTP (30 mCi) and incubated at 251C for 20 min. The beads were washed three times by microcentrifugation with cold hydrolysis buffer (20 mm Tris-HCl, pH 7.6, 50 mm NaCl, 5 mm MgCl 2 , 0.5 mm DTT, and 1 mg/ml BSA). The beads were resuspended in 100 ml hydrolysis buffer equilibrated to room temperature. Hydrolysis was carried out at 251C. Aliquots (25 ml) were removed at the indicated times (0, 20, 40 min) and quenched by the addition of 1 ml of cold washing buffer followed immediately by two washings with the same buffer. The bound nucleotides were then eluted with 20 ml of elution buffer consisting of 1% SDS and 20 mm EDTA at 651C for 5 min. The supernatants were collected by centrifugation. Samples were spotted onto polyethyleneimine-cellulose TLC plates (EM Science), which were developed in 0.75 m H 2 O 4 , pH 3.5. The plates were autoradiographed to identify GTP and GDP. The relative amounts of GTP and GDP were quantified by scanning densitometry (Alpha Innotech). The migration of authentic GTP and GDP standards was visualized using ultraviolet light at 254 nm.
Immunoblotting, immunoprecipitation, and subcellular fraction Recombinant ARHIs were analysed by 15% SDS-PAGE and transferred to PVDF membranes (Millipore). Immunoblotting for ARHI was performed with an anti-ARHI monoclonal antibody 15E11 (0.2 mg/ml), followed by ECL detection (Amersham). ARHI is expressed in normal ovarian or breast epithelial cells in relatively low levels and dramatically downregulated in most ovarian and breast cancer cells.
